Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes.

Kubitza C, Bittner F, Ginsel C, Havemeyer A, Clement B, Scheidig AJ.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):11958-11963. doi: 10.1073/pnas.1808576115. Epub 2018 Nov 5.

2.

The Involvement of the Mitochondrial Amidoxime Reducing Component (mARC) in the Reductive Metabolism of Hydroxamic Acids.

Ginsel C, Plitzko B, Froriep D, Stolfa DA, Jung M, Kubitza C, Scheidig AJ, Havemeyer A, Clement B.

Drug Metab Dispos. 2018 Oct;46(10):1396-1402. doi: 10.1124/dmd.118.082453. Epub 2018 Jul 25.

PMID:
30045842
3.

T4 lysozyme-facilitated crystallization of the human molybdenum cofactor-dependent enzyme mARC.

Kubitza C, Ginsel C, Bittner F, Havemeyer A, Clement B, Scheidig AJ.

Acta Crystallogr F Struct Biol Commun. 2018 Jun 1;74(Pt 6):337-344. doi: 10.1107/S2053230X18006921. Epub 2018 May 17.

PMID:
29870017
4.

Detoxification of Trimethylamine N-Oxide by the Mitochondrial Amidoxime Reducing Component mARC.

Schneider J, Girreser U, Havemeyer A, Bittner F, Clement B.

Chem Res Toxicol. 2018 Jun 18;31(6):447-453. doi: 10.1021/acs.chemrestox.7b00329. Epub 2018 Jun 1.

PMID:
29856598
5.

Defining the Role of the NADH-Cytochrome-b5 Reductase 3 in the Mitochondrial Amidoxime Reducing Component Enzyme System.

Plitzko B, Havemeyer A, Bork B, Bittner F, Mendel R, Clement B.

Drug Metab Dispos. 2016 Oct;44(10):1617-21. doi: 10.1124/dmd.116.071845. Epub 2016 Jul 28.

PMID:
27469001
6.

The pivotal role of the mitochondrial amidoxime reducing component 2 in protecting human cells against apoptotic effects of the base analog N6-hydroxylaminopurine.

Plitzko B, Havemeyer A, Kunze T, Clement B.

J Biol Chem. 2015 Apr 17;290(16):10126-35. doi: 10.1074/jbc.M115.640052. Epub 2015 Feb 23.

7.

Electrochemical and mARC-catalyzed enzymatic reduction of para-substituted benzamidoximes: consequences for the prodrug concept "amidoximes instead of amidines".

Bauch E, Reichmann D, Mendel RR, Bittner F, Manke AM, Kurz P, Girreser U, Havemeyer A, Clement B.

ChemMedChem. 2015 Feb;10(2):360-7. doi: 10.1002/cmdc.201402437. Epub 2014 Dec 15.

PMID:
25512261
8.

The mammalian molybdenum enzymes of mARC.

Ott G, Havemeyer A, Clement B.

J Biol Inorg Chem. 2015 Mar;20(2):265-75. doi: 10.1007/s00775-014-1216-4. Epub 2014 Nov 26. Review.

PMID:
25425164
9.

Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC).

Ott G, Plitzko B, Krischkowski C, Reichmann D, Bittner F, Mendel RR, Kunze T, Clement B, Havemeyer A.

Chem Res Toxicol. 2014 Oct 20;27(10):1687-95. doi: 10.1021/tx500174u. Epub 2014 Sep 18.

PMID:
25170804
10.

The N-reductive system composed of mitochondrial amidoxime reducing component (mARC), cytochrome b5 (CYB5B) and cytochrome b5 reductase (CYB5R) is regulated by fasting and high fat diet in mice.

Jakobs HH, Mikula M, Havemeyer A, Strzalkowska A, Borowa-Chmielak M, Dzwonek A, Gajewska M, Hennig EE, Ostrowski J, Clement B.

PLoS One. 2014 Aug 21;9(8):e105371. doi: 10.1371/journal.pone.0105371. eCollection 2014.

11.

The mitochondrial amidoxime reducing component (mARC): involvement in metabolic reduction of N-oxides, oximes and N-hydroxyamidinohydrazones.

Jakobs HH, Froriep D, Havemeyer A, Mendel RR, Bittner F, Clement B.

ChemMedChem. 2014 Oct;9(10):2381-7. doi: 10.1002/cmdc.201402127. Epub 2014 Jul 8.

PMID:
25045021
12.

Functional characterization of protein variants encoded by nonsynonymous single nucleotide polymorphisms in MARC1 and MARC2 in healthy Caucasians.

Ott G, Reichmann D, Boerger C, Cascorbi I, Bittner F, Mendel RR, Kunze T, Clement B, Havemeyer A.

Drug Metab Dispos. 2014 Apr;42(4):718-25. doi: 10.1124/dmd.113.055202. Epub 2014 Jan 14.

PMID:
24423752
13.

The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells.

Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, Bittner F, Clement B, Havemeyer A.

J Biol Chem. 2013 Jul 12;288(28):20228-37. doi: 10.1074/jbc.M113.474916. Epub 2013 May 23.

14.

Activation of the anti-cancer agent upamostat by the mARC enzyme system.

Froriep D, Clement B, Bittner F, Mendel RR, Reichmann D, Schmalix W, Havemeyer A.

Xenobiotica. 2013 Sep;43(9):780-4. doi: 10.3109/00498254.2013.767481. Epub 2013 Feb 4.

PMID:
23379481
15.

Dimethylarginine-dimethylaminohydrolase-2 (DDAH-2) does not metabolize methylarginines.

Altmann KS, Havemeyer A, Beitz E, Clement B.

Chembiochem. 2012 Nov 26;13(17):2599-604. doi: 10.1002/cbic.201200499. Epub 2012 Nov 4.

PMID:
23125090
16.

The mitochondrial Amidoxime Reducing Component (mARC) is involved in detoxification of N-hydroxylated base analogues.

Krompholz N, Krischkowski C, Reichmann D, Garbe-Schönberg D, Mendel RR, Bittner F, Clement B, Havemeyer A.

Chem Res Toxicol. 2012 Nov 19;25(11):2443-50. doi: 10.1021/tx300298m. Epub 2012 Aug 27.

PMID:
22924387
17.

The fourth mammalian molybdenum enzyme mARC: current state of research.

Havemeyer A, Lang J, Clement B.

Drug Metab Rev. 2011 Nov;43(4):524-39. doi: 10.3109/03602532.2011.608682. Epub 2011 Sep 26. Review.

PMID:
21942410
18.

Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).

Kotthaus J, Wahl B, Havemeyer A, Kotthaus J, Schade D, Garbe-Schönberg D, Mendel R, Bittner F, Clement B.

Biochem J. 2011 Jan 15;433(2):383-91. doi: 10.1042/BJ20100960.

PMID:
21029045
19.

Biochemical and spectroscopic characterization of the human mitochondrial amidoxime reducing components hmARC-1 and hmARC-2 suggests the existence of a new molybdenum enzyme family in eukaryotes.

Wahl B, Reichmann D, Niks D, Krompholz N, Havemeyer A, Clement B, Messerschmidt T, Rothkegel M, Biester H, Hille R, Mendel RR, Bittner F.

J Biol Chem. 2010 Nov 26;285(48):37847-59. doi: 10.1074/jbc.M110.169532. Epub 2010 Sep 22.

20.

Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC.

Havemeyer A, Grünewald S, Wahl B, Bittner F, Mendel R, Erdélyi P, Fischer J, Clement B.

Drug Metab Dispos. 2010 Nov;38(11):1917-21. doi: 10.1124/dmd.110.032813. Epub 2010 Aug 10.

PMID:
20699408
21.

Identification of the missing component in the mitochondrial benzamidoxime prodrug-converting system as a novel molybdenum enzyme.

Havemeyer A, Bittner F, Wollers S, Mendel R, Kunze T, Clement B.

J Biol Chem. 2006 Nov 17;281(46):34796-802. Epub 2006 Sep 13.

23.

Reduction of sulfamethoxazole and dapsone hydroxylamines by a microsomal enzyme system purified from pig liver and pig and human liver microsomes.

Clement B, Behrens D, Amschler J, Matschke K, Wolf S, Havemeyer A.

Life Sci. 2005 May 27;77(2):205-19. Epub 2005 Feb 8.

PMID:
15862605

Supplemental Content

Loading ...
Support Center